Trial reportHead & neck2019
MVA E2 therapeutic vaccine for marked reduction in likelihood of recurrence of respiratory papillomatosis.
Trial report in Head & neck, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- MVA E2 therapeutic vaccine for marked reduction in likelihood of recurrence of respiratory papillomatosis.Head & neck · 2019Trial
- Preventive and therapeutic efficacy of mRNA/LNP vaccines encoding HPV16 E6 and E7 in an early-intervention HPV tumor mouse models.Human vaccines & immunotherapeutics · 2026Article
- Recurrent Respiratory Papillomatosis Foundation Position Statement on the Management of Adults With RRP.The Laryngoscope · 2026Article
- Viral vector-based therapeutic HPV vaccines.Clinical and experimental medicine · 2024Review
- HPV Infections-Classification, Pathogenesis, and Potential New Therapies.International journal of molecular sciences · 2024Review
- The tumor microenvironment state associates with response to HPV therapeutic vaccination in patients with respiratory papillomatosis.Science translational medicine · 2023Article
- Review
- Prophylactic and Therapeutic HPV Vaccines: Current Scenario and Perspectives.Frontiers in cellular and infection microbiology · 2022Review
- How Enhancing Immunity to Low-Risk HPV Could Cure Recurrent Respiratory Papillomatosis.The Laryngoscope · 2021Review
- Biologics for the Treatment of Recurrent Respiratory Papillomatosis.Otolaryngologic clinics of North America · 2021Review
- Preclinical study of a novel therapeutic vaccine for recurrent respiratory papillomatosis.NPJ vaccines · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundRecurrent respiratory papillomatosis (RRP) or laryngeal papillomatosis is a disease caused by papillomavirus infection.
methodsIn this phase I/II clinical trial, we evaluated the efficacy of the modified vaccinia Ankara (MVA) E2 virus in the treatment of RRP. Twenty-nine patients (18 female and 11 male) underwent injection of MVA E2 directly into the borders of the vocal cords where lesions were seen and were monitored by direct laryngoscopy. The immune response was assessed by the determination of CD3
resultsLesions were completely eliminated in 13 patients (44.8%). In 16 patients (55.2%), lesions recurred between 6 and 18 months after treatment; these patients received a second round of treatment with MVA E2, and they are not seen with new recurrences.
conclusionThe MVA E2 vaccine has excellent potential for generating complete regression of RRP lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.